Cargando…

Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival?

INTRODUCTION: Dementia is a known predictor of shorter survival times in older cancer patients. However, no empirical evidence is available to determine how much a cognitive impairment shortens survival in older patients when cancer treatment is initiated. PURPOSE: To longitudinally investigate how...

Descripción completa

Detalles Bibliográficos
Autores principales: Libert, Yves, Dubruille, Stéphanie, Borghgraef, Cindy, Etienne, Anne-Marie, Merckaert, Isabelle, Paesmans, Marianne, Reynaert, Christine, Roos, Myriam, Slachmuylder, Jean-Louis, Vandenbossche, Sandrine, Bron, Dominique, Razavi, Darius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968794/
https://www.ncbi.nlm.nih.gov/pubmed/27479248
http://dx.doi.org/10.1371/journal.pone.0159734
_version_ 1782445704933801984
author Libert, Yves
Dubruille, Stéphanie
Borghgraef, Cindy
Etienne, Anne-Marie
Merckaert, Isabelle
Paesmans, Marianne
Reynaert, Christine
Roos, Myriam
Slachmuylder, Jean-Louis
Vandenbossche, Sandrine
Bron, Dominique
Razavi, Darius
author_facet Libert, Yves
Dubruille, Stéphanie
Borghgraef, Cindy
Etienne, Anne-Marie
Merckaert, Isabelle
Paesmans, Marianne
Reynaert, Christine
Roos, Myriam
Slachmuylder, Jean-Louis
Vandenbossche, Sandrine
Bron, Dominique
Razavi, Darius
author_sort Libert, Yves
collection PubMed
description INTRODUCTION: Dementia is a known predictor of shorter survival times in older cancer patients. However, no empirical evidence is available to determine how much a cognitive impairment shortens survival in older patients when cancer treatment is initiated. PURPOSE: To longitudinally investigate how much a cognitive impairment detected at the initiation of cancer treatment influences survival of older patients during a two-year follow-up duration and to compare the predictive value of a cognitive impairment on patients survival with the predictive value of other vulnerabilities associated with older age. METHODS: Three hundred and fifty-seven consecutive patients (≥65 years old) admitted for breast, prostate, or colorectal cancer surgeries were prospectively recruited. A cognitive impairment was assessed with the Montreal Cognitive Assessment (MoCA<26). Socio-demographic, disease-related, and geriatric vulnerabilities were assessed using validated tools. Univariate and subsequent multivariate Cox proportional hazards models stratified for diagnosis (breast/prostate cancer versus colorectal cancer) and disease status (metastatic versus non-metastatic) were used. RESULTS: A cognitive impairment was detected in 46% (n = 163) of patients. Survival was significantly influenced by a cognitive impairment (HR = 6.13; 95% confidence interval [CI] = 2.07–18.09; p = 0.001), a loss in instrumental autonomy (IADL ≤7) (HR = 3.06; 95% CI = 1.31–7.11; p = 0.009) and fatigue (Mob-T<5) (HR = 5.98; 95% CI = 2.47–14.44; p <0.001). CONCLUSIONS: During the two years following cancer treatment initiation, older patients with a cognitive impairment were up to six times more likely to die than patients without. Older patients should be screened for cognitive impairments at cancer treatment initiation to enable interventions to reduce morbidity and mortality. Further studies should address processes underlying the relationship between cognitive impairments and an increased risk of dying in older cancer patients.
format Online
Article
Text
id pubmed-4968794
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49687942016-08-18 Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival? Libert, Yves Dubruille, Stéphanie Borghgraef, Cindy Etienne, Anne-Marie Merckaert, Isabelle Paesmans, Marianne Reynaert, Christine Roos, Myriam Slachmuylder, Jean-Louis Vandenbossche, Sandrine Bron, Dominique Razavi, Darius PLoS One Research Article INTRODUCTION: Dementia is a known predictor of shorter survival times in older cancer patients. However, no empirical evidence is available to determine how much a cognitive impairment shortens survival in older patients when cancer treatment is initiated. PURPOSE: To longitudinally investigate how much a cognitive impairment detected at the initiation of cancer treatment influences survival of older patients during a two-year follow-up duration and to compare the predictive value of a cognitive impairment on patients survival with the predictive value of other vulnerabilities associated with older age. METHODS: Three hundred and fifty-seven consecutive patients (≥65 years old) admitted for breast, prostate, or colorectal cancer surgeries were prospectively recruited. A cognitive impairment was assessed with the Montreal Cognitive Assessment (MoCA<26). Socio-demographic, disease-related, and geriatric vulnerabilities were assessed using validated tools. Univariate and subsequent multivariate Cox proportional hazards models stratified for diagnosis (breast/prostate cancer versus colorectal cancer) and disease status (metastatic versus non-metastatic) were used. RESULTS: A cognitive impairment was detected in 46% (n = 163) of patients. Survival was significantly influenced by a cognitive impairment (HR = 6.13; 95% confidence interval [CI] = 2.07–18.09; p = 0.001), a loss in instrumental autonomy (IADL ≤7) (HR = 3.06; 95% CI = 1.31–7.11; p = 0.009) and fatigue (Mob-T<5) (HR = 5.98; 95% CI = 2.47–14.44; p <0.001). CONCLUSIONS: During the two years following cancer treatment initiation, older patients with a cognitive impairment were up to six times more likely to die than patients without. Older patients should be screened for cognitive impairments at cancer treatment initiation to enable interventions to reduce morbidity and mortality. Further studies should address processes underlying the relationship between cognitive impairments and an increased risk of dying in older cancer patients. Public Library of Science 2016-08-01 /pmc/articles/PMC4968794/ /pubmed/27479248 http://dx.doi.org/10.1371/journal.pone.0159734 Text en © 2016 Libert et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Libert, Yves
Dubruille, Stéphanie
Borghgraef, Cindy
Etienne, Anne-Marie
Merckaert, Isabelle
Paesmans, Marianne
Reynaert, Christine
Roos, Myriam
Slachmuylder, Jean-Louis
Vandenbossche, Sandrine
Bron, Dominique
Razavi, Darius
Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival?
title Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival?
title_full Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival?
title_fullStr Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival?
title_full_unstemmed Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival?
title_short Vulnerabilities in Older Patients when Cancer Treatment is Initiated: Does a Cognitive Impairment Impact the Two-Year Survival?
title_sort vulnerabilities in older patients when cancer treatment is initiated: does a cognitive impairment impact the two-year survival?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968794/
https://www.ncbi.nlm.nih.gov/pubmed/27479248
http://dx.doi.org/10.1371/journal.pone.0159734
work_keys_str_mv AT libertyves vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival
AT dubruillestephanie vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival
AT borghgraefcindy vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival
AT etienneannemarie vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival
AT merckaertisabelle vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival
AT paesmansmarianne vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival
AT reynaertchristine vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival
AT roosmyriam vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival
AT slachmuylderjeanlouis vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival
AT vandenbosschesandrine vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival
AT brondominique vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival
AT razavidarius vulnerabilitiesinolderpatientswhencancertreatmentisinitiateddoesacognitiveimpairmentimpactthetwoyearsurvival